Indian Pharmacopoeia Commission organises first-ever interactive meeting with CDL Kolkata to promote quality of medicines

New Delhi [India], August 25 (ANI): The Indian Pharmacopoeia Fee (IPC), nder the Ministry of Well being and Household Welfare, Authorities of India, organised its first-ever interactive assembly on the Central Medicine Laboratory (CDL) and Central Cosmetics Laboratory (CCL), Kolkata, specializing in strengthening pharmacopoeial requirements and drug high quality within the nation.
The assembly targeted on “IP 2026: Views, Ideas & Means Ahead”, bringing collectively specialists and stakeholders to debate the way in which ahead for pharmacopoeial requirements and drug high quality, in addition to the importance of Indian Pharmacopoeia Reference Requirements and Impurity Requirements in assuring the standard, security and efficacy of prescription drugs.
A significant spotlight of the occasion was the launch of seven Indian Pharmacopoeia Nitrosamine Impurities Reference Requirements, marking the first-ever introduction of those essential reference requirements by IPC.
The seven requirements launched are N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), N-Nitrosodibutylamine (NDBA), N-Nitrosomethylphenylamine (NMPA), N-Nitrosodiisopropylamine (NDIPA), and N-Nitroso-N-methyl-4-aminobutyric acid (NMBA).
Nitrosamines are extremely potent genotoxic and carcinogenic compounds that will come up unintentionally throughout manufacturing, storage, packaging or by way of contamination from varied supplies utilized in pharmaceutical manufacturing. Controlling these impurities is essential in some drug formulations used for hypertension, gastric problems, diabetes and tuberculosis, amongst others.
Based on the Ministry of Well being and Household Welfare, the launch of the seven impurity reference requirements will characterize a major step in direction of strengthening India’s functionality for correct detection and quantification of nitrosamine impurities in prescription drugs. The initiative will assist pharmaceutical testing, technique validation, high quality assurance and regulatory compliance, whereas selling harmonisation with worldwide high quality requirements and self-reliance in essential reference supplies.
V Kalaiselvan, Secretary-cum-Scientific Director, Indian Pharmacopoeia Fee, in his inaugural tackle, highlighted the significance of a collaborative method with the CDL laboratory in making certain the standard of medicines.
Suparna Chatterjee, Professor and Head of Pharmacology, IPGMER Kolkata, and Rakesh Kumar Rishi, Director, Central Medicine Laboratory, additionally attended the occasion.
The assembly served as a platform for specialists from regulatory authorities, laboratories and IPC to alternate views, share ideas and contribute in direction of additional strengthening the Indian Pharmacopoeia and the nationwide drug high quality ecosystem. (ANI)